These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C; Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832 [TBL] [Abstract][Full Text] [Related]
11. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. Bhatt DL; Briggs AH; Reed SD; Annemans L; Szarek M; Bittner VA; Diaz R; Goodman SG; Harrington RA; Higuchi K; Joulain F; Jukema JW; Li QH; Mahaffey KW; Sanchez RJ; Roe MT; Lopes RD; White HD; Zeiher AM; Schwartz GG; Gabriel Steg P; J Am Coll Cardiol; 2020 May; 75(18):2297-2308. PubMed ID: 32381160 [TBL] [Abstract][Full Text] [Related]
13. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M; Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437 [TBL] [Abstract][Full Text] [Related]
14. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Ostadal P; Steg PG; Poulouin Y; Bhatt DL; Bittner VA; Chua T; Diaz R; Goodman SG; Huo Y; Jukema JW; Karpov Y; Pordy R; Scemama M; Szarek M; White HD; Schwartz GG; Lancet Diabetes Endocrinol; 2022 May; 10(5):330-340. PubMed ID: 35378068 [TBL] [Abstract][Full Text] [Related]
16. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM; N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521 [TBL] [Abstract][Full Text] [Related]
17. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Szarek M; Steg PG; DiCenso D; Bhatt DL; Bittner VA; Budaj A; Diaz R; Goodman SG; Gotcheva N; Jukema JW; Pordy R; Roe MT; Sourdille T; White HD; Xavier D; Zeiher AM; Schwartz GG Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005858. PubMed ID: 31707826 [TBL] [Abstract][Full Text] [Related]
18. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Ray KK; Ginsberg HN; Davidson MH; Pordy R; Bessac L; Minini P; Eckel RH; Cannon CP Circulation; 2016 Dec; 134(24):1931-1943. PubMed ID: 27777279 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study. Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549 [TBL] [Abstract][Full Text] [Related]
20. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Diaz R; Li QH; Bhatt DL; Bittner VA; Baccara-Dinet MT; Goodman SG; Jukema JW; Kimura T; Parkhomenko A; Pordy R; Reiner Ž; Roe MT; Szarek M; Tse HF; White HD; Zahger D; Zeiher AM; Schwartz GG; Steg PG; Eur J Prev Cardiol; 2021 Mar; 28(1):33-43. PubMed ID: 33755145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]